This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Rabies Antibody Cocktail
Drug Names(s): Rabies mAb cocktail, CL184, Rabies VRVg
Description: The antibody cocktail is a combination of two human monoclonal antibodies and it is produced with the use of Crucell's MAbstract and PER.C6 technologies.
Deal Structure: Crucell has developed a human monoclonal antibody cocktail in collaboration with the Thomas Jefferson University (TJU) in Philadelphia and the US Centers for Disease Control and Prevention (CDC) in Atlanta, using MAbstract and PER.C6 technology.
Crucell is contracted with DSM Biologics, its alliance partner for the PER.C6 technology platform, for the process validation and manufacturing of antibody batches for phase III clinical efficacy studies.
In January 2008, Crucell N.V. announced that it signed an exclusive collaboration and commercialization agreement with sanofi pasteur, the vaccines division of sanofi-aventis Group, for Crucell's rabies monoclonal antibodies. Under the terms of the agreement, Crucell will continue to perform the development activities. Crucell will be responsible for the manufacturing of the final product and will retain exclusive distribution rights in Europe, co-exclusive distribution rights in China and the rights to sell to supranational...See full deal structure in Biomedtracker
Partners: Johnson & Johnson
Rabies Antibody Cocktail News
Additional information available to subscribers only: